Skandinaviska Enskilda Banken AB publ Boosts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Skandinaviska Enskilda Banken AB publ lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 78,291 shares of the biotechnology company’s stock after buying an additional 922 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in BioMarin Pharmaceutical were worth $6,051,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Dodge & Cox increased its holdings in BioMarin Pharmaceutical by 19.0% during the 2nd quarter. Dodge & Cox now owns 14,102,097 shares of the biotechnology company’s stock worth $1,176,679,000 after purchasing an additional 2,247,789 shares during the period. JPMorgan Chase & Co. increased its holdings in BioMarin Pharmaceutical by 29.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,755,379 shares of the biotechnology company’s stock worth $313,348,000 after purchasing an additional 847,367 shares during the period. Fort Washington Investment Advisors Inc. OH purchased a new stake in BioMarin Pharmaceutical during the 3rd quarter worth about $45,748,000. California Public Employees Retirement System increased its holdings in BioMarin Pharmaceutical by 40.5% during the 2nd quarter. California Public Employees Retirement System now owns 1,296,440 shares of the biotechnology company’s stock worth $108,175,000 after purchasing an additional 373,727 shares during the period. Finally, Geode Capital Management LLC increased its holdings in BioMarin Pharmaceutical by 6.5% during the 2nd quarter. Geode Capital Management LLC now owns 2,308,922 shares of the biotechnology company’s stock worth $192,379,000 after purchasing an additional 140,877 shares during the period. Hedge funds and other institutional investors own 94.15% of the company’s stock.

BioMarin Pharmaceutical stock opened at $90.22 on Friday. BioMarin Pharmaceutical Inc. has a twelve month low of $71.59 and a twelve month high of $92.17. The stock has a 50 day moving average of $86.24 and a two-hundred day moving average of $81.34. The company has a current ratio of 4.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $16.56 billion, a price-to-earnings ratio of 1,127.75, a PEG ratio of 2.90 and a beta of 0.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Tuesday, October 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.05. BioMarin Pharmaceutical had a return on equity of 2.02% and a net margin of 0.86%. The company had revenue of $408.74 million during the quarter, compared to analysts’ expectations of $435.29 million. During the same period last year, the firm earned $0.29 EPS. The firm’s revenue for the quarter was down 14.3% on a year-over-year basis. Equities analysts predict that BioMarin Pharmaceutical Inc. will post 0.29 earnings per share for the current year.

Several equities research analysts have weighed in on the company. Wedbush restated an “outperform” rating and set a $152.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, October 28th. Oppenheimer increased their price objective on BioMarin Pharmaceutical from $84.00 to $95.00 and gave the company a “market perform” rating in a report on Monday, November 22nd. Piper Sandler increased their price objective on BioMarin Pharmaceutical from $119.00 to $121.00 and gave the company an “overweight” rating in a report on Thursday, October 28th. Guggenheim increased their price objective on BioMarin Pharmaceutical from $103.00 to $120.00 and gave the company a “buy” rating in a report on Monday, November 22nd. Finally, William Blair upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Monday, November 22nd. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $110.76.

In other news, CEO Jean Jacques Bienaime sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 15th. The stock was sold at an average price of $82.71, for a total value of $496,260.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jeffrey Robert Ajer sold 2,739 shares of the firm’s stock in a transaction that occurred on Tuesday, October 26th. The shares were sold at an average price of $73.60, for a total value of $201,590.40. The disclosure for this sale can be found here. Insiders have sold a total of 15,239 shares of company stock valued at $1,267,980 over the last ninety days. 1.69% of the stock is owned by insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Featured Article: Balance Sheet

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.